The product described as 3-aminopyrrolidine dihydrochloride pharma-grade API is the crystalline dihydrochloride salt of 3-aminopyrrolidine, identified by molecular formula C4H12Cl2N2, CAS 103831-11-4, and relative molecular mass 159.06 g/mol. Because no individual monograph for this exact salt has been published in the European Pharmacopoeia or the United States Pharmacopeia, the material is controlled as a non-compendial drug substance under ICH Q7 and evaluated against general pharmacopoeial methods applicable to amine hydrochloride salts. The product is supplied for development of tablet, capsule, granule, and injectable formulations under oral and parenteral routes. The model designation is therefore not a single commercial catalogue number; it is defined by the stoichiometric salt form, assay, water content, residual solvent profile, elemental impurity profile, particle-size attributes, and route-dependent microbial or endotoxin controls.

The dihydrochloride form contains two molar equivalents of hydrogen chloride per molecule. The theoretical chloride content is 44.6% w/w and the theoretical nitrogen content is 17.6% w/w. These values provide a mass-balance check when the API is assayed after drying. Because the salt is highly water-soluble and non-volatile compared with the free base, it can be dispensed and processed in standard contained powder-handling suites. However, the acidic character of the dissolved salt requires pH buffering in injectable preparations and compatibility assessment in oral granulations. Quantitative solubility should be determined by the shake-flask method described in Ph. Eur. 2.2.8 or USP <1236> for the specific batch and intended vehicle.

What Distinguishes the Dihydrochloride Salt from the Free Base and Monohydrochloride?

The free base is a low-molecular-weight amine with pronounced odor, alkaline pH, and higher vapor pressure. These properties make direct use in solid oral dosage forms impractical without salt formation and may create occupational exposure constraints. The monohydrochloride is a crystalline intermediate that contains one molar equivalent of hydrogen chloride; it is less acidic in solution than the dihydrochloride but may still exhibit moisture uptake and partial dissociation under humid conditions. The dihydrochloride salt locks both amine sites as hydrochloride salts, producing a non-volatile crystalline powder that is easier to weigh, transfer, mill, and blend. The difference is confirmed by chloride determination by potentiometric titration per Ph. Eur. 2.3.1, pH measurement of a 1% aqueous solution per USP <791>, and loss on drying per Ph. Eur. 2.2.32.

The comparative profile of the three forms is summarized below. The table is qualitative where compendial limits are absent and should be supplemented with batch-specific characterization for each supplier.

Manufacturing of tablet, capsule, and granule forms begins with particle-size conditioning. The API is a crystalline hydrochloride that may require dry milling or screening to reduce coarse aggregates and improve blend uniformity. Particle size is measured by laser diffraction per USP <429> or Ph. Eur. 2.9.31 and reported as D10, D50, and D90; the acceptance range is formulation-dependent and is established during development rather than copied from a fixed universal specification. In direct compression development, content uniformity risk increases when the API particle size is not matched to the filler system. Stratified sampling and content uniformity testing are performed according to USP <905>. When the API load is below 10% w/w, preblending with a portion of microcrystalline cellulose or pregelatinized starch in a bin blender is a standard practice; the mixing time must be justified by blend uniformity data and is dependent on blender fill volume, rotation speed, and the flow function of the API-excipient mixture. Flow properties are characterized by angle of repose per USP <1174> and bulk and tapped density per USP <616>.

For wet granulation, the high aqueous solubility of the dihydrochloride creates a known drying risk: dissolved API can migrate to the granule surface as water is removed, producing intergranule assay variation. This is controlled by endpoint determination rather than fixed drying time. Drying in a fluid-bed dryer or tray dryer is monitored until loss on drying per Ph. Eur. 2.2.32 and water content by Karl Fischer per USP <921> Method Ia meet the established limit. Granule size distribution is measured by sieve analysis per Ph. Eur. 2.9.12 or USP <786>. Roller compaction may be preferred when aqueous granulation is not acceptable or when dry granulation is required for moisture-sensitive formulations. Tablet disintegration is evaluated by USP <701>, and dissolution method development follows ICH Q2(R1) because no compendial dissolution method exists for this specific API. Capsule fill weight variation and content uniformity are controlled according to USP <905>.

Specification release parameters for oral and parenteral development

The following matrix is representative of a pharma-grade control strategy for 3-aminopyrrolidine dihydrochloride when used as an API in solid oral and injectable dosage forms. Acceptance limits may be tightened for parenteral use or adjusted according to process capability and route-specific risk assessment. The matrix is not a harmonized monograph; it applies general chapters and ICH Q6A decision principles.

For injectable dosage forms, the API is dissolved in Water for Injection per USP <1231> and Ph. Eur. 5.1.1 compliant water quality. The resulting aqueous solution is acidic because of the two hydrochloride equivalents; pH adjustment to physiological range is required using sterile sodium hydroxide, tromethamine, or a suitable buffer system. The chloride load from the dihydrochloride must be included in tonicity calculations. Osmolality is measured by freezing-point depression per USP <785> or Ph. Eur. 2.2.35. A solution formulation should be evaluated for subvisible particles per USP <788> according to container volume, for sterility per USP <71>, and for bacterial endotoxins per USP <85>. For aseptic processing, the bulk solution is passed through a 0.22 µm sterilizing-grade membrane filter and filled into depyrogenated vials. For terminal steam sterilization, a reference cycle of 121 °C for 15 min is commonly evaluated per Ph. Eur. 5.1.1; the actual F0, dwell time, and load pattern must be based on container geometry, solution heat capacity, and pre-sterilization bioburden.

When process robustness is assessed across granulation and aseptic filling

Amine hydrochloride salts are generally hygroscopic. For this API, exposure to storage relative humidity above 60% RH for extended periods may increase water content and alter powder flow. Tightly closed containers and controlled low-humidity dispensing suites are therefore used before weighing. If water content exceeds the release limit, drying should be performed under conditions that do not cause dissociation or decomposition; loss on drying per Ph. Eur. 2.2.32 is used to confirm the drying endpoint. In aqueous granulation, the acidic pH of the dihydrochloride may accelerate hydrolysis of acid-sensitive excipients such as certain starches or ester-based polymers; compatibility should be assessed under stress storage conditions per ICH Q1A(R2). Avoid direct combination with strong alkalizing agents such as sodium hydroxide, potassium carbonate, or carbonate buffers in liquid formulations because free base liberation may reduce aqueous solubility and increase volatilization. Avoid nitrite-containing excipients in acidic formulations because the secondary pyrrolidine amine may require nitrosamine risk assessment under ICH M7 and current regional guidance.

The product also differs from related pyrrolidine building blocks such as 2-aminopyrrolidine hydrochloride or 3-hydroxypyrrolidine. The 3-amino substitution pattern creates a chiral center and provides a primary amino group with different spatial orientation, hydrogen-bonding capacity, and salt-forming behavior. If a single enantiomer is required, the optically active CAS registry number must be specified; the racemic dihydrochloride is 103831-11-4 and is not interchangeable with (R)- or (S)-enantiomer grades without revalidation. For oral granules intended for reconstitution, the acidic and saline character of the dissolved dihydrochloride may require taste masking by film coating or ion-exchange resin; the selection is based on palatability panel data and dissolution testing per USP <711>. Published data for this specific API in taste-masked oral granule formulations is limited, so development batches should establish the minimum effective coating level and confirm that release kinetics are not compromised.

For parenteral use, the same API release specification may be used for oral and injectable development, but the acceptance limits for elemental impurities, endotoxins, particulate matter, and sterility are route-dependent. Oral products may accept nonsterile microbial limits, while injectable products require sterility and endotoxin control. The dihydrochloride salt is generally preferable to the free base for injectable development because it is non-volatile and readily dissolved in aqueous vehicles; however, the acid load and chloride load must be neutralized or buffered before administration. The final pH of the injectable solution should be within physiological range, and the formulation should be checked for compatibility with glass vials, rubber stoppers, and filter membranes under ICH Q1A(R2) photolytic and thermal stress conditions. The material should not be considered interchangeable with the monohydrochloride or the free base in a validated formulation without a full bridging study that includes assay, impurity profile, pH, osmolality, and moisture behavior.